VRPX Stock Price, Virpax Pharmaceuticals, . Quote, Chart

Market Summary

USD3.10+0.18

Market Closed

6.16%

VRPX Stock Price

View Fullscreen

VRPX RSI Chart

VRPX Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.24

EV/EBITDA

0.36

Price/Free Cashflow

-0.37

MarketCap/EBT

-0.24

VRPX Price/Earnings (Trailing)

VRPX Profitability

Return on Equity

-785.26%

Return on Assets

-157.76%

Free Cashflow Yield

-271.39%

VRPX Fundamentals

VRPX Earnings

Earnings (TTM)

-15.2M

Earnings Growth (Yr)

-52.71%

Earnings Growth (Qtr)

23.9%

Breaking Down VRPX Revenue

Last 7 days

-15.8%

Last 30 days

-17.8%

Last 90 days

900%

Trailing 12 Months

354.0%

How does VRPX drawdown profile look like?

VRPX Financial Health

Current Ratio

1.25

VRPX Investor Care

Buy Backs (1Y)

0.02%

Diluted EPS (TTM)

-12.97

Tracking the Latest Insider Buys and Sells of Virpax Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 24, 2022	sendrow jerrold	bought	5,805	1.29	4,500	-
May 18, 2022	floyd eric	bought	6,107	1.3635	4,479	-
May 18, 2022	mack anthony p.	bought	101,505	1.34	75,750	chief executive officer
Nov 22, 2021	sendrow jerrold	bought	15,307	3.925	3,900	-
Nov 18, 2021	mack anthony p.	bought	100,249	3.99	25,125	chief executive officer
Feb 17, 2021	jacob gary s	bought	23,761	6.789	3,500	-
Feb 17, 2021	jambulingam thani	bought	716	7.16	100	-

Which funds bought or sold VRPX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 11, 2024	Signature Resources Capital Management, LLC	sold off	-100	-160	-	-%
Apr 11, 2024	Signature Resources Capital Management, LLC	new	-	160	160	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-48,420	32,280	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.76	-30,888	21,221	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-234,203,000	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	3,744	3,744	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	5,590	5,590	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	1.58	-2,954	2,022	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-72.00	48.00	-%
Feb 13, 2024	NORTHERN TRUST CORP	unchanged	-	-7,303	4,872	-%

Are Funds Buying or Selling VRPX?

Are funds buying VRPX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VRPX

No. of Funds

Unveiling Virpax Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 02, 2024	sabby management, llc	12.%	0	SC 13G/A
Feb 14, 2023	mack anthony p.	26.1%	3,080,566	SC 13G/A
Jan 26, 2023	kepos capital lp	0%	0	SC 13G/A
Jan 10, 2023	sabby management, llc	8.44%	988,165	SC 13G/A
Feb 14, 2022	mack anthony p.	25.2%	2,967,925	SC 13G
Feb 14, 2022	cvi investments, inc.	0%	0	SC 13G/A
Feb 04, 2022	kepos capital lp	6.4%	750,000	SC 13G

Recent SEC filings of Virpax Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	S-1/A	Initial Public Offering
Apr 18, 2024	S-1	Initial Public Offering
Apr 05, 2024	S-8	Employee Benefits Plan
Apr 03, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 01, 2024	8-K	Current Report
Jan 31, 2024	4	Insider Trading
Jan 31, 2024	4	Insider Trading

Peers (Alternatives to Virpax Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Virpax Pharmaceuticals, Inc. News

Latest updates

Virpax Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-26.2%	9,628	13,038	15,951	18,493	19,674	23,636	29,402	34,746	39,572	43,273	11,388	13,219	-	-
Current Assets	-26.2%	9,628	13,038	15,951	18,493	19,674	23,636	29,402	34,746	39,572	43,273	11,388	13,219	73.00	47.00
Cash Equivalents	-24.8%	9,142	12,153	14,804	16,987	18,995	20,563	26,061	30,797	36,842	41,713	10,467	12,264	55.00	42.00
Liabilities	17.8%	7,694	6,533	3,647	3,294	3,095	4,208	2,483	2,187	2,088	1,812	3,852	3,662	4,682	2,779
Current Liabilities	17.8%	7,694	6,533	3,647	3,294	3,095	4,208	2,483	2,187	2,088	1,812	2,830	2,640	3,660	2,779
Shareholder's Equity	-70.3%	1,934	6,506	12,305	15,199	16,579	19,428	26,919	32,559	37,485	41,461	7,536	9,558	-	-
Retained Earnings	-8.3%	-59,544	-54,982	-48,987	-45,875	-44,354	-41,367	-33,725	-27,840	-22,703	-18,586	-15,370	-13,027	-10,647	-6,308
Additional Paid-In Capital	0.0%	61,478	61,488	61,292	61,074	60,934	60,795	60,645	60,400	60,189	60,047	22,906	22,585	6,432	3,576
Shares Outstanding	0.0%	1,171	1,171	1,171	1,171	1,171	1,171	1,171	1,171	1,171	498	445	395	315	-
Float	-	-	-	9,399	-	-	-	14,615	-	-	-	9,367	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-13.6%	-3,011	-2,651	-2,182	-2,008	-1,567	-5,498	-4,736	-6,044	-4,922	-4,742	-1,797	-3,080	-150	-643	-368	-222	-
Share Based Compensation	-104.9%	-9.63	196	218	141	138	151	245	211	141	142	321	370	336	435	572	131	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-	51.00	35,989	-	15,290	-50.88	483	541	425	-

VRPX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
OPERATING EXPENSES
General and administrative (net of insurance reimbursement of $1,250,000 during the year ended December 31, 2023 – See Note 5)	$ 10,572,181	$ 11,082,463
Research and development	5,117,608	10,762,670
Total operating expenses	15,689,789	21,845,133
Loss from operations	(15,689,789)	(21,845,133)
OTHER INCOME
Other income	500,281	194,413
Loss before income taxes	(15,189,508)	(21,650,720)
Income taxes
Net loss	$ (15,189,508)	$ (21,650,720)
Basic net loss per share (in Dollars per share)	$ (12.97)	$ (18.49)
Basic weighted average common stock outstanding (in Shares)	1,171,233	1,171,020

VRPX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 9,141,512	$ 18,995,284
Prepaid expenses and other current assets	486,833	678,365
Total current assets	9,628,345	19,673,649
Total assets	9,628,345	19,673,649
Current liabilities
Accounts payable and accrued expenses	1,694,024	1,094,590
Litigation liability	6,000,000	2,000,000
Total current liabilities	7,694,024	3,094,590
Total liabilities	7,694,024	3,094,590
Commitments and contingencies
Stockholders’ equity
Preferred stock, par value $0.00001, 10,000,000 shares authorized; no shares issued and outstanding as of the years ended December 31, 2023 and 2022
Common stock, $0.00001 par value; 100,000,000 shares authorized, 1,171,233 shares issued and outstanding as of the years ended December 31, 2023 and 2022	12	12
Additional paid-in capital	61,478,444	60,933,674
Accumulated deficit	(59,544,135)	(44,354,627)
Total stockholders’ equity	1,934,321	16,579,059
Total liabilities and stockholders’ equity	$ 9,628,345	$ 19,673,649

About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

CEO	Mr. Anthony P. Mack M.B.A.
WEBSITE	virpaxpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Virpax Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Virpax Pharmaceuticals, Inc.? What does VRPX stand for in stocks?

VRPX is the stock ticker symbol of Virpax Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Virpax Pharmaceuticals, Inc. (VRPX)?

As of Fri Apr 26 2024, market cap of Virpax Pharmaceuticals, Inc. is 3.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRPX stock?

You can check VRPX's fair value in chart for subscribers.

What is the fair value of VRPX stock?

You can check VRPX's fair value in chart for subscribers. The fair value of Virpax Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Virpax Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRPX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Virpax Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether VRPX is over valued or under valued. Whether Virpax Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Virpax Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRPX.